Rheumatology

Mabpharm Raises the Stakes in Infliximab Market With a "Biobetter" Approval

July 21st 2021

By Tony Hagen

China has approved a product for rheumatoid arthritis and Crohn disease that Mabpharm and Sorrento Therapteutics say is an improvement on infliximab.

Samsung Bioepis Initiates Phase 3 Ustekinumab Trial

July 19th 2021

By Tony Hagen

Article

Samsung Bioepis launches a potential pivotal trial for its SB17 ustekinumab biosimilar candidate.

Study Supports Switch From Remicade to SB2 in IBD

July 17th 2021

By Deana Ferreri, PhD

Article

Real-world study in Italy finds most patients with inflammatory bowel disease (IBD) maintain clinical and biochemical response after switching from infliximab reference product to SB2.

Bio-Thera Moves Ustekinumab Candidate Into Phase 3 Trial

July 16th 2021

By Tony Hagen

Article

Bio-Thera's BAT2206 ustekinumab candidate is in contention with multiple other proposed biosimilars to Janssen's Stelara.

ACI Panelists Discuss Misaligned Incentives in the Biosimilars Market

July 15th 2021

By Tony Hagen

Article

Panelists at the American Conference Institute's 2021 meeting took on the complexities of biosimilar adoption in a wide-ranging discussion.

Adalimumab Biosimilar Transition Studies Reported at ECCO'21 Congress

July 13th 2021

By Tony Hagen

Article

Presentations at the European Crohn's and Colitis Organization annual meeting supported the transition to adalimumab biosimilars and provided patient acceptance data.

Study: Medicare's Lost Savings Due to Delayed Adalimumab Biosimilar Entry

July 12th 2021

By Tony Hagen

Article

Medicare lost out on over $2 billion in savings as adalimumab biosimilars were sidelined by patent restrictions, said investigators who recommended patent reforms.

Amgen US Biosimilar Trends Report Highlights Price Discounts

July 10th 2021

By Tony Hagen

Article

Biosimilars are launching at significant discounts to reference products and capturing increasing market share, according to an Amgen report.

Panel Discusses Generic, Biosimilar Marketplace Sustainability

July 9th 2021

By Tony Hagen

Article

Following the release of a whitepaper on sustainable generics and biosimilars markets, members of a trade association discussed concerning trends for the industry.

IGBA Takes Aim at Pricing Pressure and Post–COVID-19 Protectionism

July 8th 2021

By Tony Hagen

Article

In a white paper, the International Generic and Biosimilar Medicines Association (IGBA) describes industry dynamics that it says affect market sustainability and patient access.